Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2014 · 10-Q
Revenue$6.13M$6.13M−23.6% vs Q2 2013 Net Income-$8.64M-$8.64MN/M vs Q2 2013 EPS Diluted-$0.20-$0.20N/M vs Q2 2013 Gross Profit$2,417,397+12.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,667,224+36.8% Free Cash Flowderived$2,682,430+40.8% Margins · derivedGross margin39.4%+12.6 pt vs Q2 2013
Operating margin-139.1%−79.8 pt vs Q2 2013
Net margin-141.0%−85.4 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 14, 2014 · 45 d after period end